130 billion won of amlodipine sales by domestic drug companies.

Amid a feverish promotional war on amlodipine markets among the domestic drug companies to preoccupy its shares, the 2005 sales targets estimated 130 billion won for 4 different amlodipine competitors, SK's Skad, Hanmi's Amodipine, CKD's Anydipine and Choongwe's Novalopine that would be launched from Oct. this year. When Yuhan's Amlopine joins, the sales would come up to 150 billion won, which ...